Early prostate cancer: watchful waiting versus radical prostatectomy


Radical prostatectomy reduces mortality among men with localized prostate cancer; however, important questions regarding long-term benefit remain.

Between 1989 and 1999, researchers have randomly assigned 695 men with early prostate cancer to watchful waiting or radical prostatectomy and followed them through the end of 2012.

The primary end points in the Scandinavian Prostate Cancer Group Study Number 4 ( SPCG-4 ) were death from any cause, death from prostate cancer, and the risk of metastases.
Secondary end points included the initiation of androgen-deprivation therapy.

During 23.2 years of follow-up, 200 of 347 men in the surgery group and 247 of the 348 men in the watchful-waiting group died.
Of the deaths, 63 in the surgery group and 99 in the watchful-waiting group were due to prostate cancer; the relative risk was 0.56 ( P=0.001 ), and the absolute difference was 11.0 percentage points.
The number needed to treat ( NNT ) to prevent one death was 8.

One man died after surgery in the radical-prostatectomy group.

Androgen-deprivation therapy was used in fewer patients who underwent prostatectomy ( a difference of 25.0 percentage points ).

The benefit of surgery with respect to death from prostate cancer was largest in men younger than 65 years of age ( relative risk, RR=0.45 ) and in those with intermediate-risk prostate cancer ( RR=0.38 ).
However, radical prostatectomy was associated with a reduced risk of metastases among older men ( RR=0.68; P=0.04 ).

In conclusion, extended follow-up confirmed a substantial reduction in mortality after radical prostatectomy; the number needed to treat to prevent one death continued to decrease when the treatment was modified according to age at diagnosis and tumor risk.
A large proportion of long-term survivors in the watchful-waiting group have not required any palliative treatment. ( Xagena )

Bill-Axelson A et al, N Engl J Med 2014; 370:932-942

XagenaMedicine_2014



Indietro

Altri articoli

Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...


The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...


Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...


Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...


For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...